Gradient Investments’s Ionis Pharmaceuticals IONS Stock Holding History

Gradient Investments’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-91	Closed	-$3K	–	1431
2022 Q2	$3K	Hold	91	–	–	﹤0.01%	985
2022 Q1	$3K	Sell	91 -186	-67%	-$6.09K	﹤0.01%	975
2021 Q4	$8K	Buy	277 +186	+204%	+$5.86K	﹤0.01%	848
2021 Q3	$3K	Hold	91	–	–	﹤0.01%	959
2021 Q2	$4K	Hold	91	–	–	﹤0.01%	913
2021 Q1	$4K	Hold	91	–	–	﹤0.01%	915
2020 Q4	$4K	Hold	91	–	–	﹤0.01%	843
2020 Q3	$4K	Hold	91	–	–	﹤0.01%	849
2020 Q2	$5K	Sell	91 -18	-17%	-$1K	﹤0.01%	743
2020 Q1	$5K	Buy	109 +18	+20%	+$1K	﹤0.01%	779
2019 Q4	$5K	Sell	91 -24	-21%	-$1.43K	﹤0.01%	817
2019 Q3	$7K	Buy	+115	New	+$7.5K	﹤0.01%	741
2018 Q2	–	Sell	-250	Closed	-$11K	–	1061
2018 Q1	$11K	Hold	250	–	–	﹤0.01%	607
2017 Q4	$13K	Buy	+250	New	+$13.7K	﹤0.01%	548

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Gradient Investments's IONS Position: Q3 2022 in Review

Gradient Investments sold out of Ionis Pharmaceuticals (IONS) in Q3 2022, closing a stake of 91 shares — an estimated $3K sold.

Gradient Investments first reported a position in IONS in Q4 2017 and held it in 14 quarters. The position peaked at $13K in Q4 2017. 349 funds tracked by Wall St. Rank hold IONS as of Q3 2022.

Gradient Investments reported no remaining Ionis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Gradient Investments sold 91 Ionis Pharmaceuticals shares in Q3 2022, an estimated $3K.
Gradient Investments first reported a position in Ionis Pharmaceuticals in Q4 2017 and held it in 14 quarters.
Gradient Investments's Ionis Pharmaceuticals position peaked at $13K in Q4 2017.
349 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2022.

Based on Gradient Investments's 13F filing for Q3 2022, filed 14 Oct 2022.